BMO Capital Markets highlighted the potential risks faced by Real Estate Investment Trusts (REITs) specializing in Skilled Nursing Facilities (SNFs) due to possible changes in Federal Medical ...
BMO Capital Markets reaffirmed their Outperform rating on Beam Therapeutics Inc (NASDAQ:BEAM), with a steady price target of $57.00. Currently trading at $26.57, the stock appears undervalued ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback